- Erlotinib-related Severe Hair Loss with Severe Exanthematous Drug Eruption: A Case Report
-
Kang JN, Kim DH, Park SH, Seol JE, Kim H
- KMID: 2436653
- Korean J Dermatol.
- 2018 Feb;56(2):139-142.
Erlotinib inhibits the epidermal growth factor receptor and is used in patients with various cancers. However, it can affect the epidermis and hair because the receptor is expressed in normal... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Pneumatosis Cystoides Intestinalis after Erlotinib-containing Chemotherapy for Pancreatic Cancer
-
Kim GY, Kim MK, Lee DW, Han J, Kim HG
- KMID: 2448530
- Korean J Pancreas Biliary Tract.
- 2016 Jul;21(3):156-162.
- doi: 10.15279/kpba.2016.21.3.156
Pneumatosis cystoides intestinalis (PCI) is an uncommon condition that is characterized by the presence of gas within the bowel wall. We experienced a case of PCI after erlotinib-containing chemotherapy for... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acneiform Eruption Induced by Erlotinib (Tarceva(R))
-
Kim YY, Kim SY
- KMID: 2248785
- Korean J Dermatol.
- 2007 Nov;45(11):1183-1186.
Erlotinib (Tarceva(R)) is a new anticancer agent, acting as a reversible tyrosine kinase inhibitor of the epidermal growth factor receptor. It blocks signal transduction pathways implicated in the proliferation and... -
- CITED
-
- Close
- SHARE
-
- Close
- Recurrent Erlotinib-Induced Interstitial Lung Disease on Non-Small Cell Lung Cancer
-
Park SD, Kim A, Park JS, Shin CH, Nam HS, Kim L, Cho JW, Ryu JS, Kwak SM
- KMID: 2319282
- Tuberc Respir Dis.
- 2009 Nov;67(5):445-448.
Erlotinib (Tarceva(R)) has been considered to be a new, promising oral chemotherapy agent for local advanced or metastatic non-small cell lung cancer (NSCLC). Erlotinib is regarded as relatively safe, but... -
- CITED
-
- Close
- SHARE
-
- Close
- Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma
-
Hong SC, Sim YS, Lee JH, Ryu YJ, Chang JH
- KMID: 2319566
- Tuberc Respir Dis.
- 2011 Oct;71(4):286-290.
Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as... -
- CITED
-
- Close
- SHARE
-
- Close
- Erlotinib HCL (Tarceva(R)) Induced Radiation Recall Dermatitis
-
Kim HM, Lee SH, Kim CY
- KMID: 2247677
- Korean J Dermatol.
- 2010 Oct;48(10):872-875.
Erlotinib (Tarceva(R)) is a new anti-cancer agent that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell... -
- CITED
-
- Close
- SHARE
-
- Close
- Ovarian Metastasis from Non-Small Cell Lung Cancer Responding to Erlotinib
-
Jung IJ, Lim ST, Choi YS, Jang TS, Oh SH, Lee JA, Cho DY
- KMID: 2171329
- Ewha Med J.
- 2015 Mar;38(1):46-49.
- doi: 10.12771/emj.2015.38.1.46
Ovarian cancer is generally primary cancer and less frequently originates from metastasis from non-gynecological cancer. Ovarian metastasis from lung cancer represents only 2~4% of all ovarian metastatic cancers. We report... -
- CITED
-
- Close
- SHARE
-
- Close
- Sequential Responses of Adenocarcinoma of the Lung to Erlotinib after Gefitinib in Never Smoker Korean Woman
-
Kim HK, Ahn MI, Yoo J, Kim CH, Yang HJ, Shim BY
- KMID: 2166040
- Cancer Res Treat.
- 2007 Mar;39(1):37-39.
A patient with adenocarcinoma of the lung was treated sequentially using two kinds of EGFR tyrosine kinase inhibitors, gefitinib and erlotinib. The patient was a 73-year-old female who received gefitinib... -
- CITED
-
- Close
- SHARE
-
- Close
- Black Hairy Tongue Associated with Erlotinib Treatment in a Patient with Advanced Lung Cancer
-
Jeong JS, Lee JY, Kim MK, Yoon TY
- KMID: 2383260
- Ann Dermatol.
- 2011 Nov;23(4):526-528.
Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR). There have been many reports of the mucocutaneous side effects related to several EGFR inhibitors... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Acneiform Eruption and Paronychia Occurring after Use of Erlotinib (Tarceva(R))
-
Yeon JH, Min SU, Lee DH, Choi YS, Suh DH
- KMID: 2248784
- Korean J Dermatol.
- 2007 Nov;45(11):1180-1182.
Erlotinib (Tarceva(R)) is a new anti-cancer agent which acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Cicatricial Alopecia Associated with Erlotinib
-
Yang BH, Bang CY, Byun JW, Han SH, Song HJ, In SG, Shin JH, Choi GS
- KMID: 2171870
- Ann Dermatol.
- 2011 Dec;23(Suppl 3):S350-S353.
- doi: 10.5021/ad.2011.23.S3.S350
Erlotinib is a small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). Erlotinib has been used primarily to treat non-small cell lung cancer. In addition to its... -
- CITED
-
- Close
- SHARE
-
- Close
- Erlotinib-Related Spontaneous Pneumothorax in Patient with Primary Lung Cancer
-
Nam HS, Lee HJ, Kim MS, Park SW, Jeon SH, Cho JH, Kwak SM, Lee HL, Ryu JS
- KMID: 2319457
- Tuberc Respir Dis.
- 2010 Dec;69(6):465-468.
Spontaneous pneumothorax (SPTx) associated with primary lung cancer is quite rare, but has been reported as the initial presentation or a complication of disease progression. Moreover, chemotherapy-related SPTx in primary... -
- CITED
-
- Close
- SHARE
-
- Close
- Erlotinib (Tarceva(R)) Induced Hair Abnormalities
-
Choi CM, Lew BL, Sim WY
- KMID: 2247599
- Korean J Dermatol.
- 2011 Apr;49(4):382-384.
Erlotinib is a low-molecular-weight quinazoline derivative that inhibits the activation of epidermal growth factor receptor (EGFR) tyrosine kinase through competitive binding of the adenosine triphosphate binding domain of the receptor.... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
-
Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM
- KMID: 2464397
- Cancer Res Treat.
- 2019 Apr;51(2):502-509.
- doi: 10.4143/crt.2018.117
PURPOSE: We tried to evaluate whether there are any specific features in treatment outcomes of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC),... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
-
Moon DS, Jang TW, Oak CH, Jung MH, Kim DH, Choi IS
- KMID: 2257329
- Korean J Med.
- 2009 Feb;76(2):179-185.
BACKGROUND/AIMS: Lung cancer is the leading cause of cancer death worldwide. There are significant gender differences in lung cancer: most females with lung cancer are non-smokers and they are diagnosed... -
- CITED
-
- Close
- SHARE
-
- Close
- A Case of Elevated Prothrombin Time-International Normalized Ratio (PT-INR) Associated with Concurrent Use of Erlotinib and Warfarin
-
Kim SK, Park KS, Choi SH, Byun JH, Woo IS, Han CH, Kim HL
- KMID: 2259300
- Korean J Med.
- 2011 Jun;80(6):729-733.
Erlotinib, an orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is indicated for EGFR mutation-positive patients with poor performance status. Erlotinib is also used as a second-line... -
- CITED
-
- Close
- SHARE
-
- Close
- Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib
-
Oh EK, Jo DH, Kim MK, Wee WR
- KMID: 2218426
- J Korean Ophthalmol Soc.
- 2014 Feb;55(2):293-297.
- doi: 10.3341/jkos.2014.55.2.293
PURPOSE: To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively. CASE SUMMARY: Case 1, who received erlotinib, showed... -
- CITED
-
- Close
- SHARE
-
- Close
- Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients
-
Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG, Seo JY, Park I, Lee JL
- KMID: 2460603
- Cancer Res Treat.
- 2019 Oct;51(4):1549-1556.
- doi: 10.4143/crt.2019.086
PURPOSE: Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
-
Cho KM, Keam B, Kim TM, Lee SH, Kim DW, Heo DS
- KMID: 2381594
- Korean J Intern Med.
- 2015 Nov;30(6):891-898.
- doi: 10.3904/kjim.2015.30.6.891
BACKGROUND/AIMS: The purpose of this study was to identify predictive factors for erlotinib treatment in non-small cell lung cancer (NSCLC) patients following gefitinib failure. METHODS: Forty-five patients with NSCLC who were... -
- CITED
-
- Close
- SHARE
-
- Close
- Two Cases of Acneiform Eruption Caused by Epidermal Growth Factor Receptor Inhibitors
-
Choi KW, Lee CY, Lee YK, Kim HS, Kim KH, Kim YH
- KMID: 2248163
- Korean J Dermatol.
- 2008 Jun;46(6):862-865.
Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatical dermatological side effects. The most commonly encountered adverse effect is a mild skin toxicity characterized by a sterile... -
- CITED
-
- Close
- SHARE
-
- Close
